Nafamostat: all 22 studies that test it
Page 1 of 1. Open to participants first (9), then studies with results posted, then the rest; newest registration first within each.
- Nafamostat Mesylate Versus Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Sepsis-Associated Acute Kidney InjuryNot yet recruitingNCT07518303Phase 4
- The Impact of Nafamostat Mesylate on the Prognosis of Patients With Sepsis-Induced Coagulopathy Undergoing HemofiltrationNot yet recruitingNCT06994312Not applicable
- A Novel Strategy of ECMO Management Using Nafamostat for Regional Combined With Low Intensity Systematic AnticoagulationRecruitingNCT06676085Not applicable
- Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)RecruitingNCT06500793Phase 1
- Comparison of Nafamostat and Unfractionated Heparin in RRT for Sepsis Associated AKINot yet recruitingNCT06375616Phase 4
- Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMORecruitingNCT06276010Not applicable
- Nafamostat Mesilate in the Treatment of Severe Infection-associated CoagulopathyNot yet recruitingNCT06078839Phase 4
- The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot StudyRecruitingNCT05874674Not applicable
- Efficacy of Nafamostat in Covid-19 Patients (RACONA Study)RecruitingNCT04352400Phase 2/3
- Effect of Nafamostat on Postreperfusion Syndrome (PRS)CompletedNCT01001403Phase 4Results posted
- Efficacy and Safety of Nafamostat Mesylate for VV-ECMO AnticoagulationStatus unknownNCT05555641Phase 2
- Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101)CompletedNCT05090280Phase 1
- Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314Status unknownNCT04871646Phase 3
- A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 PneumoniaCompletedNCT04628143Phase 2
- A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 PneumoniaCompletedNCT04623021Phase 2
- Australasian COVID-19 Trial (ASCOT) ADAptive Platform TrialActive, not recruitingNCT04483960Phase 3
- DEFINE - Evaluating Therapies for COVID-19CompletedNCT04473053Phase 1/2
- Clinical Efficacy of Nafamostat Mesylate for COVID-19 PneumoniaStatus unknownNCT04418128Phase 2/3
- Oral Nafamostat in Healthy Volunteers (NAF-101)CompletedNCT04406415Phase 1
- Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in SenegalTerminatedNCT04390594Phase 3
- Trial to Assess the Efficacy and Safety of Nafamostat Mesilate During Continuous Renal Replacement TherapyCompletedNCT02478242Phase 4
- The Effect of Nafamostat Mesilate in Prolonging Filter Patency With Patients on Continuous Renal Replacement TherapyCompletedNCT01761994Phase 4